R&D channel feed

Seelos' stock plunges by over 75% af­ter ke­t­a­mine drug for sui­cide pre­ven­tion fails a PhII tri­al

21 hours ago

Rel­ma­da’s ma­jor de­pres­sion drug shows PhI­II promise in a fresh batch of pa­tients

21 hours ago

UCB's Eu­rope-ap­proved IL-17 au­toim­mune drug hits FDA de­lay

22 hours ago
FDA+

Taysha stops de­vel­op­ing a gene ther­a­py amid de­bate over FDA’s stance on ul­tra-rare tri­als

22 hours ago
Cell/Gene Tx

MRM open to part­ner­ships af­ter lead can­di­date im­press­es in PhI­Ia ul­cer­a­tive col­i­tis tri­al

Yesterday

Kin­nate lays off 70% of em­ploy­ees, shaves pipeline to fo­cus on CDK4 and pan-RAF in­hibitor

2 days ago
People

No­var­tis hands back PD-1 in­hibitor to BeiGene af­ter reg­u­la­to­ry hur­dles

2 days ago
Deals
FDA+

Ex­clu­sive: Backed by for­mer Google CEO’s VC, a Col­orado biotech hatch­es plat­form to evolve de­graders

2 days ago
Financing

Iver­ic, Astel­las eye US la­bel ex­pan­sion for ge­o­graph­ic at­ro­phy drug af­ter pos­i­tive two-year da­ta

2 days ago
Pharma

Ex­clu­sive: GSK re­vamps its re­search strat­e­gy, build­ing three teams to tar­get spe­cif­ic dis­ease spaces

2 days ago
People

In the Lab: Re­gen­eron brings its an­ti­body chops to gene edit­ing's biggest prob­lem, aim­ing to 'change the field'

2 days ago
In Focus

BioN­Tech nabs up to $90M for mpox vac­cine as it be­gins PhI/II tri­al be­hind Mod­er­na's lead

2 days ago
Financing
Pharma

An­thos to stop fac­tor XI tri­al in atri­al fib­ril­la­tion ear­ly af­ter 'over­whelm­ing ben­e­fit'

3 days ago

Ex­clu­sive: Backed by Il­lu­mi­na, Bro­ken String Bio­sciences rais­es $15M to find off-tar­get gene ed­its

3 days ago
Financing

FDA ap­proves GSK's JAK in­hibitor for rare blood can­cer af­ter three-month de­lay

5 days ago

Late­com­er Am­gen takes 'plat­form ap­proach' in obe­si­ty as PhII da­ta loom

6 days ago
Pharma

MAPS plans to seek ap­proval of MD­MA-as­sist­ed ther­a­py this year af­ter sec­ond pos­i­tive PhI­II tri­al

6 days ago

Bris­tol My­ers cuts mid-stage NASH, an­ti-TIG­IT pro­grams

6 days ago

Ab­b­Vie turns its back on Har­poon’s BC­MA-tar­get­ing mul­ti­ple myelo­ma drug

Last week
Deals

Mod­er­na cuts four pro­grams in vac­cines, sol­id tu­mors and heart fail­ure as it in­creas­es, pri­or­i­tizes pipeline

Last week

Gene ther­a­py biotech Alveo­Gene launch­es with lentivi­ral plat­form for res­pi­ra­to­ry dis­eases

Last week
Startups
Cell/Gene Tx

FDA sets spring de­ci­sion date for Madri­gal’s NASH treat­ment, days af­ter com­pa­ny an­nounced new CEO

Last week
FDA+

Af­ter an $80M Se­ries D raise, Dal­Cor takes an­oth­er shot at a PhI­II my­ocar­dial in­farc­tion tri­al

Last week
Financing

MaaT Phar­ma and CD­MO Skyephar­ma un­veil be­spoke, and po­ten­tial­ly largest, mi­cro­bio­me fa­cil­i­ty in Eu­rope

Last week
Manufacturing
1234 Next page Last page
A service from the Financial Times